Microdosing of scopolamine as a “cognitive stress test”: Rationale and test of a very low dose in an at‐risk cohort of older adults
Alzheimer s & Dementia March 1, 2014 Peter J. Snyder, Yen Ying Lim, Rachel Schindler et al.
Abstract: Background: Abnormal β‐amyloid (Aβ) is associated with deleterious changes in central acetylcholinergic tone in the very early stages of Alzheimer's disease (AD), which may be unmasked by a cholinergic antagonist. We aimed to establish an optimal “microdose” of scopolamine for the development of a “cognitive stress test.” Methods: Healthy older adults (n = 26, aged 55–75 years) with...